Informations générales (source: ClinicalTrials.gov)
Detection and Metabolic Characterization in DOPA PET/CT of no Treated Brain Metastases of Lung Cancer, Breast Cancer and Melanoma (DOPACER)
Interventional
N/A
Institut Cancerologie de l'Ouest (Voir sur ClinicalTrials)
décembre 2021
février 2024
19 avril 2025
About 20 to 30% of patients treated for cancer will have brain metastases. These brain
metastases are found more frequently in patients with lung cancer, breast cancer or
melanoma. The prognosis of these patients is unfavorable but prolonged survival can be
obtained with the local and systemic treatments currently available.
Brain MRI is the gold standard for evaluating brain metastases but has limitations in
therapeutic evaluation, partially offset by PET imaging of amino acid metabolism.
Our work aims to compare the performance of PET-DOPA with standard MRI for the detection
of brain metastases (≥ 5mm) in lung cancer, breast cancer and melanoma; and to
characterize these lesions using dynamic acquisitions obtained with a digital PET camera
with high spatial resolution. Having better knowledge of the metabolic characteristics of
newly discovered brain metastases, the objective of subsequent studies will be to better
assess the per- or post-therapeutic efficacy of radiotherapy and the various systemic
therapies available (chemotherapy, targeted therapy, immunotherapy).
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | BLEICHNER Sarah | 14/02/2025 09:03:15 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU Angers - 49055 - Angers - France | Pacôme FOSSE, MD | Contact (sur clinicalTrials) | |||
| Institut de Cancerologie de L'Ouest - 44055 - Saint-Herblain - France | Paul LALIRE, MD | Contact (sur clinicalTrials) | |||
| Institut de Cancerologie de l'Ouest - 49055 - Angers - France | Olivier MOREL, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Primitive cancer (brest cancer, lung cancer, melanoma) proven histologically
- Presence of brain metastasis visualized on MRI, of which at least one measures 5 mm
- Age > 18 years
- Patient has valid health insurance
- Written informed consent obtained from the patient prior to performing any
protocol-related procedures, including screening evaluations
- Primitive cancer (brest cancer, lung cancer, melanoma) proven histologically
- Presence of brain metastasis visualized on MRI, of which at least one measures 5 mm
- Age > 18 years
- Patient has valid health insurance
- Written informed consent obtained from the patient prior to performing any
protocol-related procedures, including screening evaluations
- History of irradiation cerebral
- History of brain surgery for brain metastasis or glial tumor
- Systemic therapy (chemotherapy, targeted therapy, immunotherapy) modified in the 6
weeks preceding the realization of DOPA PET/CT,
- New anti-tumor treatment started between the discovery of brain metastases and the
performance of DOPA PET/CT
- Other concomitant cancer, or history of cancer in the 5 years preceding the
performance of DOPA PET/CT
- Pregnant or lactating females
- Persons deprived of their liberty, under a measure of safeguard of justice, under
guardianship or placed under the authority of a guardian.
Disorder precluding understanding of trial information or informed consent.